114results about "Amine active ingredients" patented technology

Provided are compounds of Formula I:nucleosides, nucleoside phosphates and prodrugs thereof, wherein R6 is CN, ethenyl, 2-haloethen-1-yl, or (C2-C8)-alkyn-1-yl. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.

The technology herein provides various embodiments that relate to a method of treating pulmonary hypertension in a subject in need thereof, comprising administering to the subject an effective amount of BX-912 (N-[3-[[5-bromo-4-[2-(1H-imidazol-5-yl)ethylamino]-2-pyrimidinyl]amino]phenyl]pyrrolidine-1-carboxamide).

The invention provides novel pharmaceutical compositions of polymyxin B / trimethoprim and rifampin, as well as methods of their preparation and topical ophthalmic uses (e.g., treatment of ophthalmic infections).

To provide the use of a compound for manufacturing a reagent for efficient in vivo delivery of nucleic acid molecules, including small RNA, to a target organ and a target cell.SOLUTION: The invention provides the use of a compound derived naturally (including a traditional Chinese medicine extract) or synthetically for the manufacture of a nucleic acid delivery reagent, where the compound is represented, e.g., by the formula in the figure.SELECTED DRAWING: None

The application discloses an active oxygen response type bacteriostatic and repair promoting hydrogel and a preparation method and application thereof, the hydrogel is formed by disulfide bond cross-linked hydrogel in response to active oxygen free radicals in the vagina of vaginitis patients through thiol modified hyaluronic acid (HASH), and can enhance in-vivo retention by thiol and vaginal tissue interaction. Cationic surfactant such as didecyldimethylammonium chloride (DDAC) as the bacteriostatic component of the hydrogel, efficiently killing pathogenic bacteria while having good biocompatibility, and is not prone to cause bacterial drug resistance. As a natural immune regulator, beta-glucan regulates the vaginal microenvironment, promotes the polarization of macrophages into anti-inflammatory M2 type and promotes cell migration, etc., to promote the repair of the vaginal immune barrier, regulate the vaginal flora, and reduce the probability of vaginitis recurrence. The HASH hydrogel provides an efficient, convenient and highly transformative potential strategy to provide more choices for the treatment of vaginitis.

The present invention provides a composition comprising an imidazole or a salt thereof, and a quaternary ammonium compound for use in the treatment and / or prevention of a bacterial vaginosis. The present invention also provides a vaginal composition and a kit comprising said vaginal composition and an applicator for topically applying the vaginal composition to the vagina of a subject.

The present disclosure provides a composition, or a pharmaceutically acceptable salt thereof, comprising a a7 nicotinic acetylcholine receptor agonist and an immune checkpoint inhibitor, their pharmaceutical compositions, and methods of use for treating breast cancer with synergistic effect in reducing tumor burden and increasing survival.

The disclosure provides methods for inhibiting: tyrosinase function and / or regulation or its activity, melanogenesis, melanin production, and cell proliferation of melanomas using compounds described here, or analog(s) thereof, or compositions comprising such compounds or analog(s) thereof in a therapeutically effective amount to bind or occupy any one or more of the tyrosinase binding sites in an amount sufficient to inhibit tyrosinase (i.e., function or regulation) or its activity, inhibit melanogenesis, inhibit melanin production, even out skin pigmentation or skin tone, brighten skin pigmentation or skin tone, inhibit cell proliferation of melanomas, and ameliorate or treat skin cancer (e.g., melanoma) in a subject in need thereof.

Disclosed herein are antisense oligonucleotides, such as gapmer antisense oligonucleotides with modified backbone chemistry (e.g., with one or more spacers).Such gapmer antisense oligonucleotides with modified backbone chemistry can be useful for treating various diseases, such as neurological diseases.

In some embodiments, this disclosure describes methods for administering gamma-oscillating stimulation and agents to a target. In some embodiments, this disclosure describes methods for administering non-invasive gamma-oscillating stimulation and agents to a target. In some embodiments, this disclosure describes methods for treating neurodegeneration in subjects requiring treatment of neurodegeneration by administering gamma-oscillating stimulation and agents to a target.

This invention relates to pharmaceutical compositions, including compositions adapted for intranasal administration, comprising an active ingredient, including dexmedetomidine, pomalidomide, a selective phosphodiesterase type 4 inhibitor such as roflumilast, or combinations thereof, useful in the treatment of traumatic brain injury (TBI), including to prevent or reduce the neurological sequalae of TBI.

Aspects of the present disclosure relate to compositions and methods for treating a subject having a neurodegenerative disorder, disease or condition. Particular aspects relate to treatment with a therapeutically effective amount of a composition comprising a vector encoding an Aβ peptide variant. Further aspects relate to a method of inhibiting aggregation of endogenous Aβ peptide in vivo by contacting at least one endogenous Aβ peptide in vivo with a therapeutically effective amount of an Aβ peptide variant expressed from a vector encoding the Aβ peptide variant, said vector being present in a composition.

The present invention provides an oral solid pharmaceutical composition, comprising onradivir as an active ingredient, an alkaline reagent, and a solubilizer, and further comprising a filler. The oral solid pharmaceutical composition of the present invention effectively improves the solubility of onradivir, improves the bioavailability of onradivir in the human body, and can solve formulation issues, such as the issue where effective disintegration cannot be achieved by means of conventional formulas and processes, which is conducive to achieving the clinical application of onradivir.

This invention discloses a contraceptive antibacterial cream capable of killing HIV and sexually transmitted disease viruses, and its preparation method, belonging to the field of biopharmaceutical manufacturing technology. The contraceptive antibacterial cream comprises water, hydroxypropyl methylcellulose, benzalkonium chloride, lyophilized aloe vera gel powder, vitamin C, and functional excipients. The functional excipients are obtained by activating carboxymethyl chitosan, cross-linking it with spermine, and then coupling it with amino active molecules. The contraceptive antibacterial cream is prepared by dissolving hydroxypropyl methylcellulose in hot water to form a colloidal solution, cooling it, and then adding the remaining components and mixing thoroughly. Compared with existing technologies, the contraceptive antibacterial cream of this invention utilizes an antioxidant cycle to inhibit the oxidative degradation of benzalkonium chloride, improving product storage stability. Simultaneously, it synergistically scavenge free radicals, reducing vaginal mucosal irritation, achieving a balance of sterilization, protection, and stability while maintaining highly effective bactericidal capabilities.

This disclosure describes lipid polymer hybrid nanoparticles and methods for synthesizing such nanoparticles or compositions containing such nanoparticles. The nanoparticles are prepared in a biodegradable polymer micelle core surrounded by a lipid shell, and the majority of the pharmaceutical product is present on the inner periphery of such nanoparticles due to physical adhesion with lipid molecules. Only a small amount of the pharmaceutical product is encapsulated in the micelle core. Thus, the lipid shell becomes the primary excipient portion of the nanoparticle, and the biodegradable polymer-containing core becomes the secondary excipient portion of the nanoparticle.

The present invention provides a pharmaceutical composition for treating Wilson's disease that is effective in improving patient symptoms by improving Cu metabolism, reducing toxic free Cu, and maintaining normal Cu levels, without causing side effects. [Solution] A pharmaceutical composition for use in treating Wilson's disease in a patient requiring treatment is provided, wherein the pharmaceutical composition comprises biscolinetetrathiomolybdate, which is administered once daily in an amount of 15 mg as a delayed-release enteric-coated tablet, wherein a) the patient exhibits one or more Wilson's disease phenotypes selected from total tremor, total gait, dystonia, limb agility and coordination, and / or b) the patient has cirrhosis of the liver.

The present invention relates to the use of low concentrations of 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable salt and / or solvate thereof as an emollient in an aqueous disinfectant composition. Aqueous disinfectant compositions and their uses in one or more consumer products and disinfectant methods are also provided.

This invention discloses a method for modeling liver cancer in tree shrews, belonging to the field of disease model construction technology. (1) Reagent preparation: Under sterile conditions, weigh the required N-nitrosodiethylamine, dissolve it in sterile ultrapure water, prepare a 10 mg / mL N-nitrosodiethylamine working solution, filter it with a 0.22 μm cell filter and set it aside; Under sterile conditions, weigh the required 2-PCCA, dissolve it in sterile ultrapure water, prepare a 10 mg / mL 2-PCCA working solution, filter it with a 0.22 μm cell filter and set it aside; (2) Administer the N-nitrosodiethylamine working solution prepared in step (1) to tree shrews via intraperitoneal injection at a dose of 50 mg / kg, once a week. Three days after the administration of N-nitrosodiethylamine, administer the 2-PCCA working solution to tree shrews via gavage at a dose of 20 mg / kg. The modeling is completed in 11 consecutive weeks. To address the shortcomings of existing animal models of liver cancer, this invention proposes for the first time that the combined use of DEN and 2-PCCA can establish a stable tree shrew liver cancer model.

The present disclosure provides compositions and methods for providing a health benefit to a growing animal comprising administering a food composition to the animal, wherein the food composition includes a brain development blend. The brain development blend generally comprises DHA, EPA, taurine, choline, thiamine, riboflavin, pantothenic acid, niacin, pyridoxine, vitamin B12, and folic acid.

The invention provides fluoroalkoxyalkylene dihydroimidazo[5,1-d]tetrazinone compounds and related compounds, pharmaceutical compositions, and their use in treating cancer.

Described herein are methods for predicting treatment response to glutamate modulating agents, selecting treatment comprising glutamate modulating agents, for, and treating subjects with glutamate modulating agents, in subjects with autism spectrum disorder (ASD).

The present disclosure provides methods and compositions for reducing the addictive liability of opioid analgesics in a subject, for example, by co-administering to the subject the opioid and a serotonin receptor type 2 (5HT2) agonist or a serotonin (5HT) releasing agent. The disclosed methods include methods for preventing opioid abuse, methods for reducing the rewarding effect of an opioid, methods for reducing the addictive liability of an opioid, methods for eliminating or substantially reducing the tendency for a subject to develop physical dependence, tolerance, and / or withdrawal symptoms with respect to an opioid, and methods for eliminating or substantially reducing the tendency for a subject to use opioids in ways not prescribed, take opioids more often or in larger amounts than prescribed, and / or use opioids recreationally. The methods can be performed on a subject, such as a patient (e.g., a human patient).

Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods useful for preventing or treating osteoporosis, fracture, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia or tumoral calcinosis. Also disclosed are agonists of GLP-1R, GCGR, and / or GIPR, and methods of treating various therapeutic indications by administering an effective amount of an agonist of GLP-1R, GCGR, and / or GIPR.

The present disclosure provides methods for preventing or treating Alzheimer's disease in a subject, and / or reducing the likelihood or severity of Alzheimer's disease comprising administering to the subject an effective amount of an anti-CD33 antibody or an antigen binding fragment thereof. Alternatively, the methods comprise administering to the subject an effective amount of engineered immune cells expressing a neuronal antigen specific CAR and an anti-CD33 antibody or an antigen binding fragment thereof.

Described herein are endoxifen compositions comprising novel compounds and methods of use thereof. Methods of synthesis for the compositions are described herein. The endoxifen compositions described herein may exhibit aromatase inhibition activity or estrogen receptor activity. The endoxifen compositions described herein may be useful in the treatment of a condition in a subject, such as cancer.

The present disclosure is directed in one aspect to substituted 1,2-diamine compound inhibitors for ferroptosis, as well as pharmaceutical compositions comprising one or more of these compounds and one or more pharmaceutically acceptable excipients. The disclosure is also directed in one aspect to a method for treating, ameliorating, and / or preventing a disease or disorder comprising administering an effective amount of the pharmaceutical composition to the subject.

Methods and compositions are disclosed for rapidly relieving symptoms in subjects with depressive, stressor and substance abuse conditions, e.g., major depression, treatment-resistant depression, post-partum depression, bipolar depression, post-traumatic stress disorder, substance use disorders, negative and cognitive symptoms of schizophrenia, as well as for slowing progression of mild cognitive impairment and dementia, using an intermittent dosing regimen of memantine or amantadine or a structural analogue or pharmaceutically acceptable salt of memantine or amantadine (optionally no more frequently than every 2 days) at a dose sufficient to activate Set A brain structures, in combination with a second drug at a dose which activates Set B brain structures but which does not appreciably evoke brain activity linked to hallucinogenic and other psychotomimetic perceptions. In some instances the second drug is either 1) a low dose psilocybin or low dose of other psychedelic and stimulant molecules capable of activating Set B of brain structures which is administered at a dose low enough such that it does not appreciably evoke brain activity linked to hallucinogenic and other psychotomimetic perceptions, or is 2) mianserin (S isomer, R isomer, or a racemate comprising both isomers or structural analog or pharmaceutically acceptable salt thereof) or another standard of care antidepressant capable of activating Set B brain structures, or 3) lumateperone or another antipsychotic capable of activating Set B brain structures.